CN120569404A - 用于通过施用il-6r拮抗剂治疗风湿性多肌痛的组合物和方法 - Google Patents

用于通过施用il-6r拮抗剂治疗风湿性多肌痛的组合物和方法

Info

Publication number
CN120569404A
CN120569404A CN202380041466.3A CN202380041466A CN120569404A CN 120569404 A CN120569404 A CN 120569404A CN 202380041466 A CN202380041466 A CN 202380041466A CN 120569404 A CN120569404 A CN 120569404A
Authority
CN
China
Prior art keywords
antibody
antigen
binding fragment
week
pmr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380041466.3A
Other languages
English (en)
Chinese (zh)
Inventor
拉扎尔 J·斯隆
J·斯隆拉扎尔
Y·林
W·王
Y·刘
L·阿劳约
D·伊萨曼
K·福特
S·菲奥雷
F·马拉什
C·尼文斯
B·阿金莱德
A·詹内洛
J·柯蒂斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Biotechnology SAS
Regeneron Pharmaceuticals Inc
Original Assignee
Sanofi Biotechnology SAS
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology SAS, Regeneron Pharmaceuticals Inc filed Critical Sanofi Biotechnology SAS
Publication of CN120569404A publication Critical patent/CN120569404A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202380041466.3A 2022-04-06 2023-04-05 用于通过施用il-6r拮抗剂治疗风湿性多肌痛的组合物和方法 Pending CN120569404A (zh)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US202263327850P 2022-04-06 2022-04-06
US63/327,850 2022-04-06
US202263350761P 2022-06-09 2022-06-09
US63/350,761 2022-06-09
US202263389317P 2022-07-14 2022-07-14
US63/389,317 2022-07-14
US202263424035P 2022-11-09 2022-11-09
US63/424,035 2022-11-09
US202263424627P 2022-11-11 2022-11-11
US63/424,627 2022-11-11
US202363445331P 2023-02-14 2023-02-14
US202363445329P 2023-02-14 2023-02-14
US63/445,331 2023-02-14
US63/445,329 2023-02-14
US202363447796P 2023-02-23 2023-02-23
US63/447,796 2023-02-23
PCT/US2023/065361 WO2023196838A1 (en) 2022-04-06 2023-04-05 Compositions and methods for treating polymyalgia rheumatica by administering an il‑6r antagonist

Publications (1)

Publication Number Publication Date
CN120569404A true CN120569404A (zh) 2025-08-29

Family

ID=86424726

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380041466.3A Pending CN120569404A (zh) 2022-04-06 2023-04-05 用于通过施用il-6r拮抗剂治疗风湿性多肌痛的组合物和方法

Country Status (11)

Country Link
US (1) US20230399410A1 (https=)
EP (1) EP4504788A1 (https=)
JP (2) JP7630012B2 (https=)
KR (1) KR20240164816A (https=)
CN (1) CN120569404A (https=)
AU (1) AU2023250653A1 (https=)
CA (1) CA3247400A1 (https=)
IL (1) IL316091A (https=)
MX (1) MX2024012345A (https=)
TW (1) TW202405014A (https=)
WO (1) WO2023196838A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025149845A1 (en) * 2024-01-12 2025-07-17 Sanofi Biotechnology Treatment of subjects with polymyalgia rheumatica who have been receiving a steroid
WO2025149846A1 (en) * 2024-01-12 2025-07-17 Sanofi Biotechnology Compositions and methods for treating frail subjects with polymyalgia rheumatica by administering an il-6r antagonist

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2398076T3 (es) * 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
WO2017106312A1 (en) * 2015-12-18 2017-06-22 Drexel University Methods of modulating levels of il-6 and pd-l1
EP3980459A1 (en) * 2019-06-04 2022-04-13 Sanofi Biotechnology Compositions and methods for treating pain in subj ects with rheumatoid arthritis

Also Published As

Publication number Publication date
MX2024012345A (es) 2024-11-08
IL316091A (en) 2024-12-01
JP2025072440A (ja) 2025-05-09
TW202405014A (zh) 2024-02-01
US20230399410A1 (en) 2023-12-14
WO2023196838A1 (en) 2023-10-12
AU2023250653A1 (en) 2024-11-21
KR20240164816A (ko) 2024-11-20
EP4504788A1 (en) 2025-02-12
JP2024526414A (ja) 2024-07-18
CA3247400A1 (en) 2023-10-12
JP7630012B2 (ja) 2025-02-14

Similar Documents

Publication Publication Date Title
US20260027202A1 (en) Treatment of rheumatoid arthritis with an il-6r antibody
TWI604851B (zh) Ｉｌ－１７抗體用於製備治療強直性脊椎炎之藥物之用途
US9943594B2 (en) Methods for the treatment of rheumatoid arthritis
EP3071230B1 (en) Compositions for the treatment of rheumatoid arthritis and methods of using same
CN109963577B (zh) 用于通过施用il-4r抑制剂治疗严重特应性皮炎的方法
CN108367074A (zh) 使用白介素-17（il-17）拮抗剂治疗放射学阴性中轴型脊柱关节炎的方法
JP2025072440A (ja) Ｉｌ－６ｒアンタゴニストを投与することによってリウマチ性多発筋痛症を処置するための組成物および方法
CN115944734A (zh) 使用il-17拮抗剂抑制银屑病关节炎患者的结构损伤进展
JP2017078075A (ja) 対象の選択および治療
JP2024161517A (ja) 若年性特発性関節炎を治療するための抗ｉｌ－６受容体抗体
JP2020045351A (ja) 関節リウマチを治療するための組成物およびこれを使用する方法
CN119137149A (zh) 用于通过施用il-4r拮抗剂来治疗结节性痒疹的方法
RU2822089C2 (ru) Антитело к рецептору il-6 для лечения ювенильного идиопатического артрита
TW202547482A (zh) 已接受類固醇之具有風濕性多肌痛症之個體之治療
IL265949A (en) Preparations for the treatment of rheumatoid arthritis and methods of using them
HK1225635B (en) Compositions for the treatment of rheumatoid arthritis and methods of using same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination